BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and ...
BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company dedicated to pioneering advanced small molecule treatments for cancers driven by RAS and PI3Kα, two of the most commonly mutated oncogenes in human cancers. The company was initially formed as an offshoot of BridgeBio Pharma, a biotechnology company founded in ...BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company dedicated to pioneering advanced small molecule treatments for cancers driven by RAS and PI3Kα, two of the most commonly mutated oncogenes in human cancers. The company was initially formed as an offshoot of BridgeBio Pharma, a biotechnology company founded in 2015 by Neil Kumar, and leverages the expertise of world-leading cancer biologists. BBOT's development pipeline includes several promising programs, notably BBO-8520, BBO-10203, and BBO-11818, which are designed to modulate the KRAS and PI3K pathways. These targets are critical in a variety of solid tumors, including non-small cell lung cancer and colorectal cancer, and represent a significant area of unmet medical need.
In August 2025, BBOT became publicly traded through a business combination with Helix Acquisition Corp. II, a SPAC, successfully raising approximately $450 million in gross proceeds. This capital is intended to fund its clinical development initiatives and advance its pipeline. The company is headquartered in South San Francisco, California, and employs around 92 people, including a leadership team comprising Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer. Dr. Wallace brings extensive experience in oncology drug discovery and development, having previously led research at Amgen and other biotech firms.
Financially, BBOT is a clinical-stage company with no revenues, focusing on research and development. Its market capitalization is approximately $747 million, and it has a strong cash position, with cash per share of $8.10 and a current ratio of 6.16. The company's enterprise value is about $697 million, and it is actively investing in R&D, as evidenced by negative operating cash flow and free cash flow. The company does not pay dividends and has a significant net loss per share of -$4.95, reflecting its stage of development.
Strategically, BBOT aims to become a leader in precision oncology, targeting genetic drivers of cancer with best-in-class small molecules. The company's mission is to transform the lives of patients with RAS and PI3Kα-driven cancers, and it is positioned to capitalize on the growing demand for targeted therapies in oncology.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-134.0M
-80.5%
-34.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-114.5M
-14890.4%
-23.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.7%
—
+9.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
12.14x
+16.8%
-23.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
